Equities Analysts Offer Predictions for FMS Q3 Earnings

Fresenius Medical Care AG (NYSE:FMS) – Zacks Research boosted their Q3 2025 earnings per share estimates for shares of Fresenius Medical Care in a note issued to investors on Tuesday, May 27th. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will post earnings of $0.56 per share for the quarter, up from their prior estimate of $0.54. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q4 2025 earnings at $0.66 EPS, FY2025 earnings at $2.12 EPS, Q2 2026 earnings at $0.51 EPS, Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.68 EPS, FY2026 earnings at $2.29 EPS, Q1 2027 earnings at $0.51 EPS and FY2027 earnings at $2.32 EPS.

Several other equities research analysts have also recently weighed in on FMS. Wall Street Zen started coverage on Fresenius Medical Care in a research report on Tuesday, May 20th. They set a “strong-buy” rating on the stock. Truist Financial upped their price target on Fresenius Medical Care from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Monday, May 12th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care in a research report on Thursday, May 15th. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $27.80.

Fresenius Medical Care Trading Down 1.0%

Shares of FMS opened at $28.35 on Thursday. The business’s 50-day moving average price is $25.96 and its 200-day moving average price is $24.26. Fresenius Medical Care has a twelve month low of $17.93 and a twelve month high of $30.46. The stock has a market cap of $16.64 billion, a PE ratio of 23.43, a P/E/G ratio of 0.76 and a beta of 0.85. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. The business had revenue of $5.54 billion for the quarter, compared to analysts’ expectations of $4.71 billion.

Fresenius Medical Care Increases Dividend

The business also recently declared an annual dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 23rd will be given a dividend of $0.7871 per share. The ex-dividend date is Friday, May 23rd. This is a boost from Fresenius Medical Care’s previous annual dividend of $0.44. This represents a dividend yield of 1.9%. Fresenius Medical Care’s dividend payout ratio is currently 49.11%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of FMS. Millennium Management LLC grew its holdings in shares of Fresenius Medical Care by 5,297.5% during the fourth quarter. Millennium Management LLC now owns 722,238 shares of the company’s stock worth $16,351,000 after purchasing an additional 708,857 shares in the last quarter. Todd Asset Management LLC purchased a new position in shares of Fresenius Medical Care during the first quarter worth about $12,009,000. Teachers Retirement System of The State of Kentucky purchased a new position in shares of Fresenius Medical Care during the first quarter worth about $7,420,000. Raymond James Financial Inc. grew its holdings in shares of Fresenius Medical Care by 1,508.1% during the first quarter. Raymond James Financial Inc. now owns 287,751 shares of the company’s stock worth $7,165,000 after purchasing an additional 269,857 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Fresenius Medical Care by 3,237.7% during the first quarter. GAMMA Investing LLC now owns 239,115 shares of the company’s stock worth $5,954,000 after purchasing an additional 231,951 shares in the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.